Thompson Davis & Co’s Foundation Medicine, Inc. FMI Stock Holding History

Thompson Davis & Co’s Portfolio FMI Stock Details FMI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-50	Closed	-$4K	–	792
2018 Q1	$4K	Hold	50	–	–	0.01%	533
2017 Q4	$3K	Buy	+50	New	+$2.59K	0.01%	593
2014 Q3	–	Sell	-125	Closed	-$3K	–	1304
2014 Q2	$3K	Buy	+125	New	+$3.17K	﹤0.01%	703

Other funds holding FMI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

Thompson Davis & Co's FMI Position: Q2 2018 in Review

Thompson Davis & Co sold out of Foundation Medicine, Inc. (FMI) in Q2 2018, closing a stake of 50 shares — an estimated $4K sold.

Thompson Davis & Co first reported a position in FMI in Q2 2014 and held it in 3 quarters. The position peaked at $4K in Q1 2018. 157 funds tracked by Wall St. Rank hold FMI as of Q2 2018.

Thompson Davis & Co reported no remaining Foundation Medicine, Inc. position as of Q2 2018 after selling out during the quarter.
Thompson Davis & Co sold 50 Foundation Medicine, Inc. shares in Q2 2018, an estimated $4K.
Thompson Davis & Co first reported a position in Foundation Medicine, Inc. in Q2 2014 and held it in 3 quarters.
Thompson Davis & Co's Foundation Medicine, Inc. position peaked at $4K in Q1 2018.
157 funds tracked by Wall St. Rank held Foundation Medicine, Inc. as of Q2 2018.

Based on Thompson Davis & Co's 13F filing for Q2 2018, filed 3 Aug 2018.